Bank of America initiated coverage on shares of Metsera (NASDAQ:MTSR – Get Free Report) in a research note issued to investors on Tuesday, Marketbeat.com reports. The firm set a “buy” rating and a $38.00 price target on the stock. Bank of America‘s target price indicates a potential upside of 39.65% from the stock’s current price.
Separately, Evercore ISI began coverage on Metsera in a report on Tuesday. They set an “outperform” rating for the company.
Read Our Latest Report on MTSR
Metsera Price Performance
Metsera Company Profile
Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.
Featured Stories
- Five stocks we like better than Metsera
- What is Insider Trading? What You Can Learn from Insider Trading
- Buffett’s on the Sidelines – Should You Follow?
- What is the Euro STOXX 50 Index?
- AST SpaceMobile Stock Surges 17% After Analyst Upgrade
- Stock Analyst Ratings and Canadian Analyst Ratings
- 3 Stocks With Triple-Digit PEs That Are Still Worth a Look
Receive News & Ratings for Metsera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Metsera and related companies with MarketBeat.com's FREE daily email newsletter.
